Great post Vega. It's surprising how quickly ADC's appear to have come and gone from the hype cycle. There's lots of data coming so hopefully we'll see high-efficacy from what appears to be a good strategy.
I'd be interested in hearing your thoughts on where AI can impact clinical trials endpoints and whether bringing ctDNA, radiomics and other modalities into the right AI environment can shorten timelines for drug development and/or increase the impact on patients by directing therapy even better than "simple CDx"?
Great post Vega. It's surprising how quickly ADC's appear to have come and gone from the hype cycle. There's lots of data coming so hopefully we'll see high-efficacy from what appears to be a good strategy.
I'd be interested in hearing your thoughts on where AI can impact clinical trials endpoints and whether bringing ctDNA, radiomics and other modalities into the right AI environment can shorten timelines for drug development and/or increase the impact on patients by directing therapy even better than "simple CDx"?